首页 | 本学科首页   官方微博 | 高级检索  
     

鼻咽癌大剂量顺铂为主联合化疗合并放射的综合治疗──附88例临床分析
引用本文:李长青 皮正超. 鼻咽癌大剂量顺铂为主联合化疗合并放射的综合治疗──附88例临床分析[J]. 肿瘤防治研究, 1995, 22(1): 39-40
作者姓名:李长青 皮正超
作者单位:湖北省肿瘤医院
摘    要:
 1989年至1990年采用前瞻性随机研究治疗鼻咽癌88例。分为二组,高剂量顺铂为主联合化疗合并放射组(综合组)和单纯放射组(对照组).全组1、3年生存率分别为84.1%和46.6%,综合组和对照组的1年生存率分别为86.7%(39/45)和81.4%(35/43),P>0.05,3年生存率分别为51.1%(23/45)和41.9%(18/43),P>0.05.我们研究结果显示大剂量顺铂为主联合化疗合并放射的综合治疗对改进鼻咽癌的治疗效果仍有待进-步研究。

关 键 词:鼻咽肿瘤 药物疗法 顺铂 联合化疗 放射疗法

randomized trial of combined chemotherapy including highdose cisplatin and radiotherapy for nasopharyngeal carcinoma
Li changqing. randomized trial of combined chemotherapy including highdose cisplatin and radiotherapy for nasopharyngeal carcinoma[J]. Cancer Research on Prevention and Treatment, 1995, 22(1): 39-40
Authors:Li changqing
Affiliation:Cancer Hospital of Hubei province, wuhan
Abstract:
A prospective randomized trial in 88 nasopharyngeal carcinoma patients was conducted from 1989 to 1990 The patients were randomized into two groups, (HD-DDP+UFT) regimen plus ra-diotherapy (combined group) or radiotherapy alone. (control group). The 1-,3-year survival rates in overall groups were 84. 1% (74/88) and 46. 6% (42/88). The 1-year survival rates in the combined and control groups were 86. 7% (39/45) and 81. 4% (35/43) (P>0.05). The 3 -year survival rates were5l. 1% (23/45) and 41. 9% (18/43),respectively (P>0. 05). Our pre-liminary results show that combined chemotherapy including highdose cisplatin and radiotherapy may improve the therapeutic result of nasopharyngeal carcinoma.
Keywords:
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号